Atossa Genetics (ATOS) Competitors $0.83 -0.01 (-1.21%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$0.83 0.00 (-0.12%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. ORKA, ATAI, RAPP, RGNX, ERAS, ABVX, FULC, ITOS, BNTC, and RVNCShould you be buying Atossa Genetics stock or one of its competitors? The main competitors of Atossa Genetics include Oruka Therapeutics (ORKA), atai Life Sciences (ATAI), Rapport Therapeutics (RAPP), REGENXBIO (RGNX), Erasca (ERAS), Abivax (ABVX), Fulcrum Therapeutics (FULC), iTeos Therapeutics (ITOS), Benitec Biopharma (BNTC), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry. Atossa Genetics vs. Its Competitors Oruka Therapeutics atai Life Sciences Rapport Therapeutics REGENXBIO Erasca Abivax Fulcrum Therapeutics iTeos Therapeutics Benitec Biopharma Revance Therapeutics Oruka Therapeutics (NASDAQ:ORKA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Which has more risk & volatility, ORKA or ATOS? Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Does the media refer more to ORKA or ATOS? In the previous week, Oruka Therapeutics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 2 mentions for Oruka Therapeutics and 1 mentions for Atossa Genetics. Oruka Therapeutics' average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of ORKA or ATOS? 56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 24.7% of Oruka Therapeutics shares are owned by insiders. Comparatively, 7.6% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate ORKA or ATOS? Oruka Therapeutics currently has a consensus price target of $40.38, suggesting a potential upside of 220.56%. Atossa Genetics has a consensus price target of $6.17, suggesting a potential upside of 645.67%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Atossa Genetics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has higher earnings & valuation, ORKA or ATOS? Atossa Genetics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOruka TherapeuticsN/AN/A-$83.72M-$4.51-2.79Atossa GeneticsN/AN/A-$25.50M-$0.21-3.94 Is ORKA or ATOS more profitable? Oruka Therapeutics' return on equity of -25.66% beat Atossa Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Oruka TherapeuticsN/A -25.66% -23.39% Atossa Genetics N/A -33.90%-31.53% SummaryOruka Therapeutics beats Atossa Genetics on 7 of the 12 factors compared between the two stocks. Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$109.68M$6.86B$5.53B$9.05BDividend YieldN/A1.21%5.24%4.03%P/E Ratio-3.9418.0519.7920.15Price / SalesN/A99.70421.02118.60Price / CashN/A21.0936.8958.07Price / Book1.454.748.045.67Net Income-$25.50M$173.18M$3.18B$249.13M7 Day Performance-5.97%1.33%2.82%3.30%1 Month Performance-3.51%-0.41%3.70%5.20%1 Year Performance-29.32%28.42%35.41%21.38% Atossa Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Genetics1.4893 of 5 stars$0.83-1.2%$6.17+645.7%-29.3%$109.68MN/A-3.948News CoverageORKAOruka Therapeutics2.2161 of 5 stars$10.90-6.7%$40.38+270.4%N/A$408.10MN/A-2.42N/ANews CoverageATAIatai Life Sciences3.0149 of 5 stars$2.02-18.5%$8.67+329.0%+116.8%$404.69M$310K-2.2280Analyst ForecastOptions VolumeGap DownHigh Trading VolumeRAPPRapport Therapeutics1.3542 of 5 stars$10.88-0.4%$32.67+200.2%-48.3%$397.12MN/A-3.15N/APositive NewsRGNXREGENXBIO4.5266 of 5 stars$7.86-6.8%$31.63+302.4%-19.3%$394.26M$83.33M-2.53370Positive NewsERASErasca3.0918 of 5 stars$1.39+1.5%$4.57+228.9%-36.7%$393.77MN/A-2.24120ABVXAbivax2.4206 of 5 stars$6.11+2.3%$31.00+407.4%-39.0%$387.68MN/A0.0061News CoveragePositive NewsGap UpFULCFulcrum Therapeutics0.3385 of 5 stars$7.17+2.6%$6.29-12.3%+13.8%$387.03M$80M-102.41100ITOSiTeos Therapeutics3.2205 of 5 stars$10.11+1.5%$15.86+56.8%-31.2%$386.95M$35M-3.3390BNTCBenitec Biopharma1.6189 of 5 stars$14.57-0.3%$23.83+63.6%+48.6%$382.46M$80K-9.6520High Trading VolumeRVNCRevance Therapeutics2.7987 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500 Related Companies and Tools Related Companies ORKA Alternatives ATAI Alternatives RAPP Alternatives RGNX Alternatives ERAS Alternatives ABVX Alternatives FULC Alternatives ITOS Alternatives BNTC Alternatives RVNC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATOS Stock Alerts